Predictive value of recurrence of solid and micropapillary subtype in lung adenocarcinoma.

Abstract

INTRODUCTION:

Although histological subtype in lung adenocarcinoma has been reported as a poor prognostic factor in several studies, its utility has not yet been revealed as an adaptation criterion of postoperative adjuvant chemotherapy.

MATERIALS AND METHODS:

Four hundred ninety-four lung adenocarcinoma patients were enrolled in this retrospective study. A sub-analysis was performed in 420 lung adenocarcinoma patients with pathological stage 0-I disease for risk factors of postoperative recurrence.

RESULTS:

Maximum standardized uptake value (SUVmax) (p<0.01), pathological stage ≥II (p<0.04), and adjuvant chemotherapy (p<0.01) were risk factors for recurrence in the multivariate analysis, whereas histological subtype was not a significant factor for recurrence at all stages. In the sub-analysis, univariate analysis showed that carcinoembryonic antigen expression (p<0.01), prognostic nutrition index (p=0.03), SUVmax (p<0.01), lymphatic invasion (p<0.01), vascular invasion (p<0.01), grade 3-4 differentiation (p<0.01), pathological stage ≥IA3 (p<0.01), and histological subtype (p=0.03) were significant risk factors of recurrence. SUVmax (p<0.01) was the only risk factor for recurrence in the multivariate analysis, whereas histological subtype was not (p=0.07). Relapse-free survival (RFS) was significantly worse in the micropapillary- and solid-predominant subtype groups than in the other subtypes (p=0.01). On the other hand, RFS by with or without uracil-tegafur as adjuvant chemotherapy in lung micropapillary-predominant or solid-predominant adenocarcinoma patients with pathological stage IA-IB disease was not significantly different.

CONCLUSION:

This study suggested that histological subtypes such as micropapillary- or solid-predominant pattern are risk factors for recurrence in pathological stage 0-I lung adenocarcinoma and may be necessary adjuvant chemotherapy instead of uracil-tegafur.

• Authors: Nozomu Motono, Takaki Mizoguchi, Masahito Ishikawa, Shun Iwai, Yoshihito Iijima, Hidetaka Uramoto
• Journal: Oncology (Oncology) (Oct 27 2023) ISSN: 1423-0232 [Electronic] Switzerland
• PMID: 37899040 (Publication Type: Journal Article)
• Copyright: S. Karger AG, Basel.